Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-label Study of Eribulin Mesylate in Previously Treated Advanced Soft Tissue Sarcoma
jRCT2080221635Phase 2
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eribulin in soft tissue sarcoma (STS), sponsored by Eisai Co., Ltd.
02
Drugs
eribulin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on jRCT2080221635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221635.